Tuesday, May 16, 2000

Genentech Appoints Myrtle Potter to EVP of Commercial Operations and COO

South San Francisco, Calif. -- May 16, 2000 --

Genentech, Inc. (NYSE: DNA) today announced the appointment of Myrtle S. Potter to executive vice president of Commercial Operations and chief operating officer. Potter is the former president of U.S. Cardiovascular/Metabolics, a multi-billion dollar business of Bristol-Myers Squibb Corporation. She will lead Genentech's commercial operations, including the Sales, Marketing and Business Development functions.

"Myrtle's appointment will strengthen Genentech's senior management and provide experienced strategic leadership," said Arthur D. Levinson, Ph.D., Genentech's chairman and chief executive officer. "With seven drugs currently on the market, two preparing for launch this year, one preparing for FDA filing and seven in late-stage clinical trials, our commercial operations are poised for substantial growth in the coming years. Genentech will be well served by Myrtle's significant industry experience and proven leadership in this area."

Potter, 41, joined Bristol-Myers Squibb in 1996 as vice president, Strategy and Economics. She was promoted to group vice president, Worldwide Medicines Group and then to senior vice president of Sales, U.S. Cardiovascular/Metabolics before becoming president of that business unit. Prior to joining Bristol-Myers Squibb, Potter spent 14 years at Merck and Company, Inc. She rose through Merck's Sales and Marketing organizations eventually holding the title of vice president, Northeast Region Business Group.

This year, Potter was named "Woman of the Year" by the Healthcare Businesswomen's Association. In 1999, she was honored by the Association of Black Cardiologists as the first African-American woman to head a division of a major pharmaceutical company. Potter holds a bachelor's degree from the University of Chicago.

Genentech, Inc. is a leading biotechnology company that discovers, develops, manufactures and markets human pharmaceuticals for significant unmet medical needs. Thirteen of the approved products of biotechnology stem from Genentech science, seven of which Genentech markets directly in the United States. The company has headquarters in South San Francisco, California.

# # #